WebApr 4, 2024 · In a setback to biotechnology company Illumina ( NASDAQ:ILMN ), the U.S. Federal Trade Commission (FTC) has ordered it to unwind the $7 billion acquisition of cancer detective test maker Grail. The regulator believes that the Grail acquisition impacts competition and innovation in the U.S. market for cancer tests. WebApr 3, 2024 · The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer. The move …
Illumina, Inc., and GRAIL, Inc., In the Matter of Federal …
WebApr 4, 2024 · The U.S. Federal Trade Commission reversed on Monday an administrative law judge’s decision to dismiss antitrust charges initially brought in a complaint by FTC … WebApr 3, 2024 · The FTC said Illumina gave Grail special pricing and other benefits. “Real world evidence of Ilumina’s past behavior reinforces the Commission’s antitrust concerns,” the commission said. The regulator said it rejects Illumina’s claim that this acquisition will likely yield results that save lives. synonyms for impassive
Illumina Ordered by FTC to Unwind Grail Purchase From 2024 (1)
WebApr 5, 2024 · Carl Icahn said Illumina's efforts to appeal a Federal Trade Commission order to divest its highly contested Grail acquisition "is an almost impossible battle." The … WebApr 3, 2024 · The Federal Trade Commission rejected Illumina Inc.’s $7 billion deal for cancer-test developer Grail Inc., a fresh sign the commission wants to take a more aggressive stance toward deal-making. WebApr 12, 2024 · In Illumina-Grail, the FTC prohibited Illumina from acquiring without prior approval for 10 years any ownership in Grail or any other business that engaged or had plans to engage in the development, marketing, or sale of multicancer early detection tests. On March 31, 2024, the FTC ordered Illumina to divest the $7.1 billion acquisition of ... thai venice florida